Clinical Trials

78 enrolled

Neoplasm Metastasis, Neoplasms

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Neoplasms

NCT07247110 2026-03-11

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

250 enrolled

Neoplasms

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

681 enrolled

Phase 1 Not yet recruiting

Neoplasm Metastasis, Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Neoplasm Metastasis

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

15 enrolled

Adenocarcinoma, Neoplasms

NCT02560636 2026-01-06

PLUMMB

34 enrolled

Neoplasm Metastasis

NCT05270213 2025-12-19

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

164 enrolled

Neoplasm Metastasis, Neoplasms

NCT05165433 2025-12-16

FORTIFY

14 enrolled

Carcinoma, Neoplasm Metastasis

NCT06108050 2025-12-16

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

177 enrolled

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT06724042 2025-12-10

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

159 enrolled

Neoplasm Metastasis

NCT05338658 2025-12-09

Study of PAT in Patients With Solid Tumor Cancers

21 enrolled

Neoplasm Metastasis

NCT04520711 2025-11-19

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

24 enrolled

Carcinoma

NCT03486301 2025-11-12

EIK1001

87 enrolled

Neoplasms

NCT04840394 2025-11-12

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

1 enrolled

Neoplasms

NCT06188208 2025-10-16

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

125 enrolled

Neoplasms

NCT05514444 2025-10-09

MK-4464-001

64 enrolled

Neoplasms

NCT03564691 2025-10-07

MK-4830-001

470 enrolled

Neoplasms

NCT05501821 2025-09-25

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

16 enrolled

Neoplasms

NCT06983743 2025-09-11

AURORAS-1

200 enrolled

Neoplasm Metastasis, Neoplasms

NCT05378425 2025-09-09

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

90 enrolled

Neoplasm Metastasis, Neoplasms

NCT06415487 2025-07-01

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

30 enrolled

Neoplasm Metastasis

NCT04648202 2025-06-27

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

82 enrolled

Neoplasm Metastasis

NCT03260322 2025-04-24

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

169 enrolled

Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

829 enrolled 100 charts

Neoplasms

NCT02794571 2024-12-05

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

518 enrolled

Neoplasm Metastasis

NCT05349890 2024-11-25

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

1 enrolled

Carcinoma

NCT03568058 2024-11-13

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

30 enrolled

Neoplasms

NCT04130542 2024-10-31

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

276 enrolled

Neoplasms

NCT04659629 2024-10-01

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

59 enrolled

Neoplasms

NCT03447314 2024-09-23

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

54 enrolled 40 charts

Neoplasms

NCT03873883 2024-09-19

IO-001

119 enrolled

Neoplasms

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

104 enrolled

Neoplasms

NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

165 enrolled

Neoplasms

NCT05232409 2023-04-20

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

72 enrolled

Neoplasm Metastasis

NCT04859777 2021-09-16

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Phase 1 Unknown

70 enrolled

Neoplasm Metastasis, Neoplasms

NCT01848834 2021-06-28

MK-3475-012

297 enrolled 21 charts

Neoplasms

NCT02303990 2021-05-12

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

59 enrolled 9 charts

Neoplasms

NCT02722954 2020-08-11

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

29 enrolled

Neoplasm Metastasis, Neoplasms

NCT02620423 2018-09-13

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

11 enrolled